We identify and share funding opportunities as they arise to help advance MPT research and development. The items below are listed from the earliest to latest application due dates. We encourage you to browse below and contact us if you hear of any new opportunities.

Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R01 Clinical Trial Optional)

This funding opportunity from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), and Office of Research on Women’s Health (ORWH) will support projects with the aim to understand factors that impact uptake and adherent and persistent use of biomedical HIV prevention options, to inform and advance approaches to support choice and use among these options, and to understand and advance equitable delivery of biomedical HIV prevention options for cisgender and transgender women in settings where multiple prevention options are available. Additional details can be found here or at www.GRANTS.gov by searching within “Search Grants” for Notice of Funding Opportunity (NOFO): RFA-MH-24-160, then clicking on the opportunity number.

  • NOFO #: RFA-MH-24-160
  • Open Date: 22 October 2023
  • Letters of Intent Due: 30 days prior to application receipt date
  • Next Application Due: 22 November 2023

*Also see Companion Funding Opportunities: RFA-MH-24-162 (R34 Planning Grant) and RFA-MH-24-161 (R21 Exploratory/Developmental Grant)

Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional) 

This funding opportunity from the National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and National Institute of Mental Health (NIMH) will support the continued development of new and innovative on-demand, event-driven, and long-acting multipurpose prevention technologies. Applications may involve MPT development, as well as socio-behavioral studies on end-user preferences and other factors that could promote increased MPT adoption and use. Additional details can be found here or at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: PAR-22-222, then clicking on the opportunity number.

  • Funding Opportunity #: PAR-22-222
  • Open Date: 07 November 2022
  • Letters of Intent Due: Not applicable
  • Next Application Due: 07 December 2023

Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R43/R44 Clinical Trial Not Allowed)

This funding opportunity from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will support the development of new and innovative long-acting systemic and non-systemic multipurpose prevention technologies (MPT). The FOA includes support the development and/or acceptability of MPTs in adolescent and young women. Additional details can be found here or at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: PAR-21-297, then clicking on the opportunity number.

  • Funding Opportunity #: PAR-21-297
  • Open Date: 09 November 2021
  • Letters of Intent Due: 30 days prior to application receipt date
  • Next Application Due: 09 December 2023

Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R41/R42 Clinical Trial Not Allowed)

This funding opportunity from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH) will support development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods) in adolescent and young women. Additional details can be found here or at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: PAR-21-298, then clicking on the opportunity number.

  • Funding Opportunity #: PAR-21-298
  • Open Date: 09 November 2021
  • Letters of Intent Due: 30 days prior to application receipt date
  • Next Application Due: 09 December 2023

Biological Testing Facility (X01 Clinical Trial Not Allowed)

This funding opportunity from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will provide investigators with a mechanism to request services from this facility that would advance their contraceptive development program. This NOFO aims to position innovative and validated methods for future clinical development. Additional details can be found here or at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: PAR-23-192, then clicking on the opportunity number.

  • Funding Opportunity #: PAR-23-192
  • Open Date: 30 April 2023
  • Letters of Intent Due: Not applicable
  • Next Application Due: 02 January 2024

Catalytic Opportunity Fund: For Introduction and Scale Up of New and Lesser Used Reproductive Health Products

The Clinton Health Access Initiative (CHAI) will reopen their Catalytic Opportunity Fund (COF) at the end of April to new applications for DMPA-SC Scale Up, DMPA-SC Regulatory Advocacy, and Hormonal IUD Scale Up. Find out more about these opportunities here. 

Comprehensive Resources for HIV Microbicides and Biomedical Prevention (CRMP)

This contract provides gap-filling support services for HIV prevention drug developers including academic (investigators), for-profit and not-for-profit small and large companies, and other product innovators (henceforth identified as Sponsors) for the development of HIV non-vaccine biomedical prevention (nBP) strategies and products. The types of nBPs supported include, but are not limited to, topical microbicides, pre-exposure prophylaxis (PrEP) and Multipurpose Prevention Technologies (MPT’s) for the purpose of preventing HIV transmission and acquisition in adolescents, women, men and transgender individuals. Sponsors seeking these services receive no funding from NIAID, but instead receive products or information generated by NIAID-funded contractors on their behalf. Data and reports are provided in a format that supports a regulatory filing. Additional details can be found here.

  • Who can use this resource?
    • Sponsors must have a defined need or gap that is delaying or blocking further advancement of their product to clinical testing and/or licensure.
    • Sponsors need preliminary data and/or regulatory agency input supporting a justification for the requested support.
    • If in support of a specific grant activity, the Sponsor needs to demonstrate a critical need to the advancement of the grant objectives that cannot be met by rebudgeting or administrative supplement, if applicable.  
  • How to get started: Follow the procedures for requesting access to NIAID contract services
  • Application Due: Rolling basis

MCI-BCM Sponsored Target Screening

This ongoing funding scheme offers the opportunity to utilize state-of-the-art facilities at Baylor College of Medicine to screen validated male contraceptive targets for small-molecule inhibitors using DNA-Encoded Chemistry Technology. Applications are accepted on an ongoing, rolling basis. Learn more and apply here.